TKI Discontinuation and Chronic Myeloid Leukemia

Share this content:
TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.
TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) can yield impressive survival rates among those patients who achieve sustained bone-marrow complete cytogenetic response (CCyR).1 These patients now have an expected survival rate “comparable to that of the general population,” experts noted.1

Current clinical practice involves lifelong continuation of TKI therapy, which tends to be well-tolerated overall.2 But lifelong TKI therapy can become a financial burden for some patients; TKIs can also preclude the possibility of pregnancy.

Clinical studies tend to focus on grade 3 and 4 toxicities—adverse events that can be severe enough to prompt discontinuation.  But in the setting of lifelong TKI therapy, even low-grade side effects can become important concerns.

For some patients, furthermore, long-term TKI therapy can cause late endocrine, cardiovascular, pulmonary, and gastrointestinal toxicities, as well as myalgia, rash, peripheral edema, or musculoskeletal symptoms.3

Increasingly, patients are approaching their oncologists about the possibility of TKI discontinuation after CCyR. 4 Patient concerns and health care cost considerations have prompted research into the possibility of sustained treatment-free remission for some patients.

RELATED: Adding Pioglitazone to Imatinib May Improve Response Rate in CML

The depth of clinical response is determined using hematologic and cytogenetic assessments. CCyR involves the absence of Philadelphia chromosome-positive (Ph+) cells; molecular responses are measured with reverse-transcriptase PCR from marrow or blood samples, typically as the ratio of BCR-ABL1 to ABL transcripts (log-scale BCR-ABL1 percentage).

Page 1 of 2
Loading links....

Related Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters